Oncology Central

The potential detrimental effect of corticosteroids in prostate cancer


Diagnosis of prostate cancer (PC) at local or regional stages is associated with an excellent prognosis [1]; however, patients with metastatic PC generally achieve only temporary disease control with hormonal therapy and they eventually develop disease progression despite castrate serum androgen levels. In the last years the number of drugs available for metastatic castration-resistant prostatic cancer (mCRPC), such as abiraterone, cabazitaxel, enzalutamide and sipuleucel-T, has rapidly increased [2].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.